CRT set to initiate Ph I trial of GSK's aurora kinase blocker
UK charity Cancer Research UK and its Cancer Research Technology unit will begin a Phase I trial of a cancer drug from UK drug major GlaxoSmithKline.
GSK's 1070916A, an aurora kinase inhibitor, is the third drug to enter Cancer Research UK's Clinical Development Partnerships program, but the first that is ready to be used in patients.
Cancer Research UK will sponsor the trial, at the Institute of Oncology at St James' University Hospital in Leeds as well as Barts and The London's Experimental Cancer Medicine Centre in London. The trial will be managed by the charity's drug development office and will start within the next year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze